Summary:
Have you been diagnosed with pyoderma gangrenosum? Are you currently experiencing an inflammatory episode?
If so, you may be eligible to participate in a study to evaluate gevokizumab in subjects in the acute inflammatory phase of pyoderma gangrenosum.
We are looking for patients that are:
- Male or female, at least 18 years or older
- Diagnosed with pyoderma gangrenosum, with at least one new active ulcer
- Not pregnant, or breast-feeding
- Not HIV- and/or Hepatitis C positive
What can you expect?
Over a 3 month period you will receive 3 doses of the investigational medication and participate in a total of 9 visits.
If you are eligible, you may receive:
- Investigational medication
- Study-related office visits and laboratory testing
- Compensation for time and travel